Rezolute Inc RZLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.37
- Day Range
- $4.14–4.65
- 52-Week Range
- $1.07–11.46
- Bid/Ask
- $4.00 / $4.61
- Shares Outstanding
- 96.29M
- Market Cap
- $443.91M
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute’s pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 71
- Website
- https://www.rezolutebio.com
Valuation
|
Metric
|
RZLT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.80 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
RZLT
Financial Strength
|
Metric
|
RZLT
|
|---|---|
Quick Ratio | 15.61 |
Current Ratio | 15.84 |
Interest Coverage | — |
Quick Ratio
RZLT
Profitability
|
Metric
|
RZLT
|
|---|---|
Return on Assets (Normalized) | −49.61% |
Return on Equity (Normalized) | −53.99% |
Return on Invested Capital (Normalized) | −57.86% |
Return on Assets
RZLT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|g?T<t<b | LOCK|>Sk>H | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|k&bP&@ | LOCK|lWxwg | $71B | |||
| argenx SE ADR
ARGX
| LOCK|w%PnfS | LOCK|h!# | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!l&&q% | LOCK|N@ | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|yGBS#p | LOCK|^T?ln | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Tb!h@VH# | LOCK|!QY@K | $26B | |||
| Moderna Inc
MRNA
| LOCK|k<vs&d> | LOCK|fs& | $25B | |||
| Incyte Corp
INCY
| LOCK|l&M!!R# | LOCK|JY? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|@j>%rjR | LOCK|^h | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|?v$J%K | LOCK|J% | $16B |
United States